Table Graph
   

tocilizumab - versus placebo - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.92 [0.69, 1.23]< 10%4 studies (4/-)71.8 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %NAnot evaluable crucial-
deaths 1.01 [0.78, 1.30]< 10%6 studies (6/-)48.1 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 1.03 [0.77, 1.38]< 10%2 studies (2/-)42.1 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.76 [0.38, 1.51]< 165%2 studies (2/-)78.2 %some concernnot evaluable moderateimportant-
clinical improvement 1.12 [0.95, 1.33]> 10%3 studies (3/-)91.6 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.15 [0.90, 1.47]> 10%1 study (1/-)86.8 %NAnot evaluable important-
death or ventilation 0.81 [0.57, 1.16]< 133%3 studies (3/-)87.5 %some concernnot evaluable moderateimportant-
hospital discharge 1.05 [0.88, 1.25]> 113%2 studies (2/-)70.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.67 [0.39, 1.14]< 10%1 study (1/-)93.0 %NAnot evaluable important-
ICU admission 0.48 [0.25, 0.94]< 10%1 study (1/-)98.4 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.86 [0.67, 1.11]< 10%3 studies (3/-)88.0 %some concernnot evaluable moderateimportant-
adverse events 1.11 [0.74, 1.67]< 141%2 studies (2/-)29.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons